Menu

Brain Trauma (Closed Head Injury)

Postgrad Med J. 2004 Nov;80(949):650-3.

Management of Traumatic Brain Injury: Some Current Evidence and Applications.

Guha A.

Walton Centre for Neurology and Neurosurgery and University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Traumatic brain injury remains a worldwide problem. Newer modalities in the management of such injuries include both drugs and therapeutic strategies. Continuing research in animal models has provided a better understanding of the pathophysiological processes that follow head injury, and this in turn has enabled workers to work on improved treatment targets. Although there are exciting and novel approaches emerging, there is no substitute for meticulous initial resuscitation. Additionally, some of the more well known management options are now better understood. These concepts are discussed in the article.

PMCID: PMC1743133, PMID: 15537849 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/15537849

 


 

Pain Res Manag. 2001 Summer;6(2):67-73.

The Cannabinoids: An Overview. Therapeutic Implications in Vomiting and Nausea After Cancer Chemotherapy, in Appetite Promotion, in Multiple Sclerosis and in Neuroprotection.

Mechoulam R, Hanu L.

Hebrew University, Jerusalem, Israel.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The present paper describes the historical use of cannabis, starting with its use in Assyria and China. Recent advances in the understanding of the molecular basis of cannabis action are explained, including the identification of the cannabinoid receptors CB(1) and CB(2), as well as the isolation of endogenous cannabinoids from the brain and periphery. The use of Δ9-tetrahydrocannabinol as an anti-vomiting and anti-nausea drug for cancer chemotherapy, and as an appetite-enhancing agent is described. Clinical work in multiple sclerosis, which may lead to the approval of tetrahydrocannabinol as a drug for this condition, is presented. Preclinical and clinical investigations with cannabidiol, a non-psychotropic cannabis constituent, are also described. Recent work with cannabidiol in animal models of rheumatoid arthritis may lead to clinical investigations. A synthetic cannabinoid, HU-211 (Dexanabinol), is in advanced clinical stages of investigation as a neuroprotectant in head trauma. The above clinical approaches may ultimately lead to the realization that cannabinoids are valuable clinical drugs in numerous fields.

PMID: 11854768 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/11854768